US National Cancer Institute to test seven novel cancer drugs from Clavis Pharma
Clavis Pharma announced that the US National Cancer Institute has accepted seven new compounds from the company for testing under its Developmental Therapeutics Program. The drug candidates, which are structurally novel analogues of several cancer drugs, have been synthesized by applying Clavis Pharma's proprietary Lipid Vector Technology. The drug candidates will be screened in a well-established cell line test panel (NCI-60) against a variety of cancer types. Positive pre-clinical results from the NCI screening program, will constitute important pre-clinical documentation for these products and potentially contribute to the broadening of Clavis Pharma's oncology pipeline. Previously Clavis' two most advanced drug candidates, Elacyt(TM) and CP.4126, have also undergone similar NCI screening.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.